PDB Short entry for 2L23 HEADER TRANSCRIPTION 10-AUG-10 2L23 TITLE NMR STRUCTURE OF THE ACID (ACTIVATOR INTERACTING DOMAIN) OF THE HUMAN TITLE 2 MEDIATOR MED25 PROTEIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION SUBUNIT 25; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: ACID DOMAIN, UNP RESIDUES 391-548; COMPND 5 SYNONYM: MEDIATOR COMPLEX SUBUNIT 25, ACTIVATOR-RECRUITED COFACTOR 92 COMPND 6 KDA COMPONENT, ARC92, ACTIVATOR INTERACTION DOMAIN-CONTAINING PROTEIN COMPND 7 1, P78; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: ACID1, ARC92, MED25, PTOV2, TCBAP0758; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET KEYWDS HUMAN MEDIATOR COMPLEX, PANCREATIC TUMOR OVEREXPRESSED DOMAIN, KEYWDS 2 TRANSCRIPTION EXPDTA SOLUTION NMR NUMMDL 20 AUTHOR F.BONTEMS,D.MONTE,F.DEWITTE,V.VILLERET REVDAT 3 18-AUG-21 2L23 1 REMARK SEQADV REVDAT 2 30-MAR-11 2L23 1 JRNL REVDAT 1 24-NOV-10 2L23 0 JRNL AUTH F.BONTEMS,A.VERGER,F.DEWITTE,Z.LENS,J.L.BAERT,E.FERREIRA, JRNL AUTH 2 Y.LAUNOIT,C.SIZUN,E.GUITTET,V.VILLERET,D.MONTE JRNL TITL NMR STRUCTURE OF THE HUMAN MEDIATOR MED25 ACID DOMAIN. JRNL REF J.STRUCT.BIOL. V. 174 245 2011 JRNL REFN ISSN 1047-8477 JRNL PMID 20974256 JRNL DOI 10.1016/J.JSB.2010.10.011 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CYANA 2.1 REMARK 3 AUTHORS : GUNTERT, MUMENTHALER AND WUTHRICH REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2L23 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 12-AUG-10. REMARK 100 THE DEPOSITION ID IS D_1000101859. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 293 REMARK 210 PH : 6.75 REMARK 210 IONIC STRENGTH : 120 REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 0.3-0.5 MM [U-98% 13C U-98% 15N] REMARK 210 MED25, 10 MM SODIUM PHOSPHATE, REMARK 210 100 MM SODIUM CHLORIDE, 5 MM DTT, REMARK 210 90% H2O/ 10% D2O; 0.3-0.5 MM [U- REMARK 210 100% 15N] MED25, 10 MM SODIUM REMARK 210 PHOSPHATE, 100 MM SODIUM REMARK 210 CHLORIDE, 5 MM DTT, 90% H2O/10% REMARK 210 D2O; 0.3-0.5 MM [U-95% 13C] REMARK 210 MED25, 10 MM SODIUM PHOSPHATE, REMARK 210 100 MM SODIUM CHLORIDE, 5 MM DTT, REMARK 210 100% D2O; 0.2 MM [U-100% 15N] REMARK 210 MED25, 10 MM SODIUM PHOSPHATE, REMARK 210 100 MM SODIUM CHLORIDE, 5 MM DTT, REMARK 210 100% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-15N HSQC; 2D 1H-13C HSQC; REMARK 210 3D HNCA; 3D HNCACB; 3D HNCO; 3D REMARK 210 CBCA(CO)NH; 3D HNHA; 3D HCCH- REMARK 210 TOCSY; 3D 1H-15N NOESY; 3D 1H- REMARK 210 13CALI NOESY; 3D 1H-13CARO NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 950 MHZ; 600 MHZ; 800 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE III REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : CCPNMR ANALYSIS REMARK 210 METHOD USED : TORSION ANGLE DYNAMICS REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 20 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : ALL CALCULATED STRUCTURES REMARK 210 SUBMITTED REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 465 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 MODELS 1-20 REMARK 465 RES C SSSEQI REMARK 465 HIS A 162 REMARK 465 HIS A 163 REMARK 465 HIS A 164 REMARK 465 HIS A 165 REMARK 465 HIS A 166 REMARK 465 HIS A 167 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 ALA A 12 -64.05 -100.83 REMARK 500 1 TRP A 13 118.03 -163.67 REMARK 500 1 LYS A 89 -68.17 -105.70 REMARK 500 1 LEU A 91 -60.79 -90.20 REMARK 500 1 ILE A 100 -70.22 -90.31 REMARK 500 1 THR A 114 -71.46 -90.44 REMARK 500 1 PRO A 116 91.73 -69.76 REMARK 500 1 GLU A 118 102.69 -56.54 REMARK 500 1 LYS A 130 -24.22 -145.55 REMARK 500 2 SER A 5 -177.52 -62.56 REMARK 500 2 ALA A 12 -66.16 -96.22 REMARK 500 2 LYS A 22 74.72 65.22 REMARK 500 2 PRO A 23 -170.23 -69.80 REMARK 500 2 LYS A 24 141.86 66.38 REMARK 500 2 SER A 27 108.97 -50.10 REMARK 500 2 ASN A 31 20.83 -151.80 REMARK 500 2 LEU A 34 103.25 -52.21 REMARK 500 2 ASN A 45 170.13 -55.01 REMARK 500 2 LYS A 51 89.83 -66.13 REMARK 500 2 ILE A 100 -68.96 -90.21 REMARK 500 2 HIS A 113 54.52 -109.30 REMARK 500 2 ALA A 115 160.41 63.56 REMARK 500 2 PRO A 116 92.44 -69.77 REMARK 500 2 LYS A 130 -32.78 -167.52 REMARK 500 2 LYS A 131 61.11 72.37 REMARK 500 3 ALA A 12 -66.17 -97.71 REMARK 500 3 LYS A 22 72.30 59.90 REMARK 500 3 ASN A 31 13.68 -140.03 REMARK 500 3 LEU A 34 101.47 -55.15 REMARK 500 3 ASN A 45 170.07 -55.67 REMARK 500 3 LYS A 51 89.45 -68.67 REMARK 500 3 LEU A 72 30.49 -96.38 REMARK 500 3 ILE A 100 -69.63 -90.59 REMARK 500 3 PRO A 116 78.62 -69.73 REMARK 500 3 LYS A 130 -30.06 -179.62 REMARK 500 3 PHE A 144 -61.15 -90.11 REMARK 500 3 GLN A 159 -74.63 -122.28 REMARK 500 4 GLN A 3 -50.89 -123.83 REMARK 500 4 ALA A 12 -67.79 -100.37 REMARK 500 4 TRP A 13 118.56 -161.19 REMARK 500 4 LEU A 34 101.15 -54.44 REMARK 500 4 LYS A 51 89.89 -66.38 REMARK 500 4 LEU A 72 31.70 -96.58 REMARK 500 4 PRO A 116 85.53 -69.78 REMARK 500 4 GLU A 118 101.91 -54.99 REMARK 500 4 LYS A 130 -27.35 -142.86 REMARK 500 4 LYS A 131 52.77 70.89 REMARK 500 4 VAL A 158 143.09 -172.52 REMARK 500 5 ALA A 12 -66.04 -101.28 REMARK 500 5 ASP A 29 -41.41 -130.02 REMARK 500 REMARK 500 THIS ENTRY HAS 268 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 650 REMARK 650 HELIX REMARK 650 DETERMINATION METHOD: AUTHOR DETERMINED DBREF 2L23 A 2 159 UNP B9TX31 MED25_HUMAN 126 283 SEQADV 2L23 MET A 1 UNP B9TX31 INITIATING METHIONINE SEQADV 2L23 LEU A 160 UNP B9TX31 EXPRESSION TAG SEQADV 2L23 GLU A 161 UNP B9TX31 EXPRESSION TAG SEQADV 2L23 HIS A 162 UNP B9TX31 EXPRESSION TAG SEQADV 2L23 HIS A 163 UNP B9TX31 EXPRESSION TAG SEQADV 2L23 HIS A 164 UNP B9TX31 EXPRESSION TAG SEQADV 2L23 HIS A 165 UNP B9TX31 EXPRESSION TAG SEQADV 2L23 HIS A 166 UNP B9TX31 EXPRESSION TAG SEQADV 2L23 HIS A 167 UNP B9TX31 EXPRESSION TAG SEQRES 1 A 167 MET GLY GLN GLN SER VAL SER ASN LYS LEU LEU ALA TRP SEQRES 2 A 167 SER GLY VAL LEU GLU TRP GLN GLU LYS PRO LYS PRO ALA SEQRES 3 A 167 SER VAL ASP ALA ASN THR LYS LEU THR ARG SER LEU PRO SEQRES 4 A 167 CYS GLN VAL TYR VAL ASN HIS GLY GLU ASN LEU LYS THR SEQRES 5 A 167 GLU GLN TRP PRO GLN LYS LEU ILE MET GLN LEU ILE PRO SEQRES 6 A 167 GLN GLN LEU LEU THR THR LEU GLY PRO LEU PHE ARG ASN SEQRES 7 A 167 SER ARG MET VAL GLN PHE HIS PHE THR ASN LYS ASP LEU SEQRES 8 A 167 GLU SER LEU LYS GLY LEU TYR ARG ILE MET GLY ASN GLY SEQRES 9 A 167 PHE ALA GLY CYS VAL HIS PHE PRO HIS THR ALA PRO CYS SEQRES 10 A 167 GLU VAL ARG VAL LEU MET LEU LEU TYR SER SER LYS LYS SEQRES 11 A 167 LYS ILE PHE MET GLY LEU ILE PRO TYR ASP GLN SER GLY SEQRES 12 A 167 PHE VAL ASN GLY ILE ARG GLN VAL ILE THR ASN HIS LYS SEQRES 13 A 167 GLN VAL GLN LEU GLU HIS HIS HIS HIS HIS HIS HELIX 1 1 GLN A 67 ARG A 77 5 11 HELIX 2 3 LEU A 91 GLY A 104 1 14 HELIX 3 4 ASP A 140 LYS A 156 1 17 SHEET 1 A 8 LEU A 10 GLN A 20 0 SHEET 2 A 8 THR A 35 VAL A 44 -1 O CYS A 40 N GLY A 15 SHEET 3 A 8 SER A 79 PHE A 86 -1 O GLN A 83 N TYR A 43 SHEET 4 A 8 ILE A 132 PRO A 138 -1 O PHE A 133 N PHE A 84 SHEET 5 A 8 LEU A 122 SER A 127 -1 N MET A 123 O LEU A 136 SHEET 6 A 8 PHE A 105 HIS A 110 -1 N VAL A 109 O LEU A 122 SHEET 7 A 8 LYS A 58 PRO A 65 -1 N ILE A 64 O ALA A 106 SHEET 8 A 8 LEU A 10 GLN A 20 1 N GLU A 18 O MET A 61 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000